G. Robb

发表

A chemistry wiki to facilitate and enhance compound design in drug discovery.

M. Waring, G. Robb, D. Mckerrecher, 2013, Drug discovery today.

Matched molecular pairs as a medicinal chemistry tool.

Daniel J. Warner, Andrew G. Leach, A. Leach, 2011, Journal of medicinal chemistry.

Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant GTPase KRASG12C.

Doyle J Cassar, J. Breed, D. Ogg, 2020, Journal of medicinal chemistry.

Development of a novel BCL6 PROTAC to provide insight into small molecule targeting of BCL6

David M. Wilson, Qing Cao, M. Waring, 2018 .

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.

David M. Wilson, Qing Cao, M. Waring, 2018, ACS chemical biology.

Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.

Matthew Grist, C. Chuaqui, Qing Cao, 2017, Journal of medicinal chemistry.

Fragment-Based Design of a Potent MAT2a Inhibitor and in Vivo Evaluation in an MTAP Null Xenograft Model.

S. Tentarelli, M. Vázquez‐Chantada, E. Chiarparin, 2021, Journal of medicinal chemistry.

Discovery of a series of 2-(pyridinyl)pyrimidines as potent antagonists of GPR40

M. Waring, P. Macfaul, D. Baker, 2015 .

Discovery of a series of 5-AzaQuinazolines as orally efficacious IRAK4 inhibitors targeting MyD88L265P mutant Diffuse Large B Cell Lymphoma.

A. Bloecher, L. Drew, R. Anjum, 2019, Journal of medicinal chemistry.

Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.

L. Drew, R. Anjum, Yafeng Xue, 2018, Bioorganic & medicinal chemistry.

Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy.

A. Bailey, Robert D. M. Davies, Alastair J. H. Brown, 2017, Journal of medicinal chemistry.

Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.

S. Kazmirski, Nancy Su, D. Ogg, 2015, ACS medicinal chemistry letters.

Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.

B. Barlaam, P. Macfaul, S. Pearson, 2018, ACS medicinal chemistry letters.

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).

Nichola L. Davies, B. Barlaam, S. Degorce, 2018, Journal of medicinal chemistry.

Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C.

Doyle J Cassar, Nichola L. Davies, J. Breed, 2022, Journal of medicinal chemistry.

The discovery of a novel series of glucokinase activators based on a pyrazolopyrimidine scaffold.

Ulrik Jurva, Volker Schnecke, M. Waring, 2012, Bioorganic & medicinal chemistry letters.

Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma.

Nichola L. Davies, A. Ferguson, L. Drew, 2017, Journal of medicinal chemistry.

Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle.

R. A. Thompson, Jonas Pettersson, Jan Kihlberg, 2012, Drug discovery today.

Potent and selective bivalent inhibitors of BET bromodomains.

A. Dulak, A. Rabow, M. Waring, 2016, Nature chemical biology.

Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.

R. Anjum, Yafeng Xue, James S. Scott, 2020, Bioorganic & medicinal chemistry.

Free Ligand 1D NMR Conformational Signatures to Enhance Structure Based Drug Design of a Mcl-1 inhibitor (AZD5991) and other Synthetic Macrocycles.

Nichola L. Davies, E. Chiarparin, M. Lamb, 2019, Journal of medicinal chemistry.

Design of pyrazolo-pyrimidines as 11β-HSD1 inhibitors through optimisation of molecular electrostatic potential

James S. Scott, G. Robb, J. Swales, 2015 .

Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656

Michael J. Waring, Graeme R. Robb, David S. Clarke, 2012 .

Identification of pyrazolo-pyrimidinones as GHS-R1a antagonists and inverse agonists for the treatment of obesity

Nathaniel G. Martin, Robert D. M. Davies, P. Macfaul, 2013 .

Identification, optimization, and pharmacology of acylurea GHS-R1a inverse agonists.

Nathaniel G. Martin, Robert D. M. Davies, Alastair J. H. Brown, 2014, Journal of medicinal chemistry.

Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation.

M. Waring, D. M. Andrews, R. Rowlinson, 2014, Chemical Communications.

Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors.

Nichola L. Davies, Yafeng Xue, James S. Scott, 2022, Bioorganic & medicinal chemistry.

Comparison of Receptor–Ligand Restraint Schemes for Alchemical Absolute Binding Free Energy Calculations

J. Michel, G. Robb, D. Cole, 2023, Journal of chemical theory and computation.

Optimization of brain penetrant 11β-hydroxysteroid dehydrogenase type I inhibitors and in vivo testing in diet-induced obese mice.

James S. Scott, A. Turnbull, T. Sjögren, 2014, Journal of medicinal chemistry.

Learning Medicinal Chemistry Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Rules from Cross-Company Matched Molecular Pairs Analysis (MMPA).

Jérôme Hert, Christian Kramer, Martin Stahl, 2017, Journal of medicinal chemistry.

Discovery of potent, selective small molecule inhibitors of α-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIα).

M. Waring, D. M. Andrews, G. Robb, 2015, Bioorganic & medicinal chemistry letters.

Drugging the undruggable: a computational chemist's view of KRASG12C.

Michael S Bodnarchuk, Jason G Kettle, Graeme Robb, 2021, RSC medicinal chemistry.

An industrial evaluation of proteochemometric modelling: Predicting drug-target affinities for kinases

Lewis H. Mervin, O. Engkvist, Astrid Stroobants, 2023, Artificial Intelligence in the Life Sciences.

Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration.

Doyle J Cassar, Nichola L. Davies, J. Breed, 2023, Journal of medicinal chemistry.

Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.

K. Coopman, G. Robb, G. Willars, 2011, Molecular endocrinology.

Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092

Michael J. Waring, Graeme R. Robb, M. Waring, 2011 .

Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.

K. Coopman, G. Robb, G. Willars, 2011, Molecular endocrinology.

Achieving improved permeability by hydrogen bond donor modulation in a series of MGAT2 inhibitors

Philip A. MacFaul, Graeme R. Robb, Andrew G. Leach, 2013 .

Matched triplicate design sets in the optimisation of glucokinase activators – maximising medicinal chemistry information content

Michael J. Waring, David Hargreaves, Nathaniel G. Martin, 2013 .

Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.

L. Drew, R. Anjum, Yafeng Xue, 2018, Bioorganic & medicinal chemistry.

Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors.

V. Kantae, N. Grimster, M. Lamb, 2024, Journal of medicinal chemistry.

Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.

B. Barlaam, P. Johnström, M. Schou, 2024, Journal of medicinal chemistry.